Advanced Neural Biosciences, Inc.

What Advanced Neural Biosciences, Inc. does

Advanced Neural Biosciences, Inc. is a privately held biomedical research company founded in 2016 that operates two specialized research programs in neural cryobiology and cerebral ischemia. In neural cryobiology, the company develops vitrification protocols aimed at achieving ice-free preservation of brain tissue, building on a peer-reviewed publication in Rejuvenation Research in 2020. In cerebral ischemia, the company is developing compounds and protocols intended to limit brain damage following stroke or cardiac arrest, with two additional papers reported in preparation for 2025. The company maintains dual research facilities in Portland, Oregon and Brooklyn, New York, and is led by CEO Aschwin de Wolf and President Chana Phaedra.

The company's core technology is a portfolio of experimental protocols and candidate compounds rather than a commercialized product platform. No patents, licensed products, or standardized protocols for clinical or research-customer delivery are disclosed in the available data; the public-facing artifacts are scientific papers and a WordPress-hosted informational website. Technical components mentioned include vitrification methodology (ice-free cryopreservation) and ischemia-intervention compounds, but no underlying platform architecture, instrumentation, or productized tooling is described.

The business model is not commercially articulated. No revenue, customers, pricing, grants, partnerships, or funding rounds are disclosed across any source block. The company therefore functions in practice as a research-output entity producing peer-reviewed publications, with no visible near-term path to product revenue. The implied monetization pathway — if any exists — would run through future licensing, contract research, or grant funding, but none of these are documented in the input.

Name

Advanced Neural Biosciences, Inc.

Legal name

Advanced Neural Biosciences, Inc.

Website

https://advancedneuralbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Advanced Neural Biosciences is a privately held biomedical research company founded in 2016 that develops vitrification protocols for ice-free brain cryopreservation and compounds for cerebral ischemia treatment, operating research facilities in Portland, OR and Brooklyn, NY.

Ownership category

akta.pro rank

Product category

Biomedical Cryobiology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

akta.pro secondary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Neural cryopreservation
• Brain vitrification research
• Cerebral ischemia studies
• Central nervous preservation
• Biomedical research services

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Advanced Neural Biosciences is a biomedical research company developing vitrification solutions for ice-free cryopreservation of the mammalian brain and central nervous tissue, as well as proprietary compounds and protocols to depress cerebral metabolism and restore blood flow to the brain after stroke and cardiac arrest. The company's work supports brain banking, pharmacological drug discovery, and neurodegenerative disease research.

Product overview

Advanced Neural Biosciences, Inc. is a biomedical research company (not a product company) with two primary research focus areas: Neural Cryobiology and Cerebral Ischemia Research. Neural Cryobiology focuses on perfecting low temperature technologies to preserve central nervous tissue and whole brains for brain banking, pharmacological drug discovery, and neurodegenerative disease research. Cerebral Ischemia Research develops compounds to restore optimal blood flow to the brain after stroke and cardiac arrest. The company operates research facilities in Portland, Oregon and Brooklyn, New York.

Differentiator

Problem solved

Functional benefit

Products and services

• Neural Cryobiology Research Research program developing vitrification solutions for ice-free cryopreservation of the central nervous system and whole mammalian brains, preserving ultrastructural detail and biological viability. The solutions are engineered for negligible toxicity, low viscosity, and optimal blood-brain barrier penetration. Used for brain banking, pharmacological drug discovery, and neurodegenerative disease research.
• Cerebral Ischemia Research Research program developing novel compounds and protocols that depress cerebral metabolism and improve blood flow to the brain after ischemic events such as stroke and cardiac arrest. The technologies also enable ice-free cryopreservation of the brain when there is a delay between circulatory arrest and cryopreservation procedures.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves5 records

Expansion highlights2 records

Direct peers

• 21st Century Medicine: Long-standing cryobiology R&D company developing vitrification solutions and ice-free preservation protocols for organs and tissues. Directly comparable to ANB because both pursue the same fundamental goal — ice-free cryopreservation of complex mammalian tissues — using proprietary cryoprotectant chemistry, and serve overlapping downstream customers in organ banking and cryonics.
• Alcor Life Extension Foundation: Leading cryonics service provider that performs whole-body and neuro-cryopreservation of humans. Comparable to ANB because Alcor is a primary potential end-user/customer for CNS vitrification solutions and is an active research publisher in the same scientific niche as ANB's neural cryobiology program.
• Cryonics Institute: Michigan-based cryonics organization performing whole-body cryopreservation with associated research activity. Comparable to ANB as another operator/potential customer in the CNS cryopreservation value chain and a publisher in the cryobiology field adjacent to ANB's research focus.

Broad incumbents

• Celularity Inc. Publicly traded regenerative medicine company developing cell therapies derived from placental and other tissues. Comparable to ANB in the broader regenerative/biologics space and as a supplier of biological materials to research and drug-discovery customers, though at far greater scale and with a different therapeutic focus.
• BioTime (Lineage Cell Therapeutics): Clinical-stage cell therapy and regenerative medicine company. Comparable to ANB as a peer operating in regenerative medicine and tissue engineering, with overlapping scientific talent pools though a fundamentally different commercial scale and stage.

Emerging players

• Rejuvenate Bio: Early-stage biotech developing gene therapies to counter age-related disease. Comparable to ANB in operating at the intersection of neurodegeneration, longevity, and central nervous system research, with overlapping customer/collaborator networks in the longevity science community.
• Tomorrow Biostasis: European cryopreservation service provider focused on standby and storage of cryopreserved patients. Comparable to ANB as a downstream customer/user of advanced cryoprotectant technology and a participant in the same neural-cryopreservation ecosystem.
• Sylvatica Biotech: Startup developing cryopreservation technology for organs and complex tissues using ice-free approaches. Comparable to ANB as a peer working on next-generation vitrification methods at a similar early stage, though focused on organs other than the brain.
• Ossium Health: Company banking bone marrow and other cellular products for transplant and research, working on cell and tissue preservation logistics. Comparable to ANB in tissue-banking infrastructure and supply to research institutions, though Ossium's portfolio is cellular rather than whole-organ.

Others

• Athersys: Clinical-stage biotech developing cell therapies for stroke and other inflammatory conditions. Comparable to ANB in targeting the stroke/ischemia therapeutic indication ANB's cerebral ischemia program addresses, though Athersys operates as a much larger publicly-listed drug developer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/advanced-neural-biosciences-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Neural Biosciences, Inc.